Fezolinetant – November 2025

• Brand names:
  • Veoza®
• Pharmaceutical Company:
  • ASTELLAS PHARMA AUSTRALIA PTY LTD
• Condition/Indication: Moderate to severe menopause-related vasomotor symptoms (VMS)
• Meeting Date: November 2025
• Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.4MB)
• Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 1.0MB)